FDA Policy/General

Commissioner Pick Faces Potentially Lengthy Senate Confirmation

Now that president Donald Trump has officially nominated White House health policy adviser Heidi Overton to become FDA commissioner, a quick Senate confirmation appears unlikely.

In an 8/19 Truth Social post, Trump characterized Overton as a “rockstar” in the administration, “where she has worked directly with Secretary Kennedy, Dr. Oz, and team, to deliver on the MOST TRANSFORMATIVE Health Agenda in History.” Trump said Overton is “known to take on the HARDEST issues, and bring me solutions that work best for the Country.”

Trump said Overton would “deliver on my priorities of FASTER Cures, INCREASED American Innovation, MAJOR Clinical Trial Reforms, LOWER Drug Prices, and even more MAHA WINS!”

Steven Grossman, a former HHS official and Senate HELP Committee staffer, said a confirmation vote before the midterm elections “seems unlikely, although there may be a White House-led effort to ram a nomination through in late September.”

In a statement provided to FDA Webview, Grossman noted that the Senate is scheduled to be in session for only about three weeks before the election and that the financial disclosure and vetting process can take weeks before a hearing is scheduled. He also said support from all Republican senators for a quick confirmation “is far from a given.”

If confirmation is pushed back until the lame-duck session, predicting when or how the nomination will proceed could become difficult, according to Grossman.

“If the House or Senate flip, there is a notion that Republicans will rush forward with bills and nominations that won’t be viable after a change in control,” he said. “The reality can be different: departing Members sometimes stay home and are often reluctant to decide issues that they feel should be addressed by the newly-elected Congress.”

Already, there is some pushback from Capitol Hill. Sen. Bill Cassidy (R-LA) said in a post on X that he has “strong concerns” about Overton’s nomination. “Her lack of managerial experience does not prepare her well for leading a large organization that is already dealing with staffing and morale issues,” Cassidy said. “Additionally, Dr. Overton’s active role in last week’s nonsensical vaccine executive order calls into question her commitment to standing up for sound science and protecting children’s health. That alone is almost disqualifying.”

Cassidy’s comments suggest that Overton’s connection to the administration’s vaccine policy could receive significant scrutiny during the confirmation process. She appeared at a White House event (see story) associated with the executive order proposing changes to the nation’s childhood vaccination recommendations. Her views and role in developing the administration’s health policies are likely to be a major focus if the nomination moves forward.

Gupta Raises Concerns About Overton’s Independence, Ideology

FDA commissioner nominee Heidi Overton’s responses on vaccines, contraception and abortion medication during her 9/24 Senate confirmation hearing raise concerns that ideology could influence her decision-making if she takes over the agency, MSNBC senior medical analyst Dr. Vin Gupta said Friday. Gupta was particularly critical of Overton’

Overton Confirmation Remains Uncertain After Senate Hearing

FDA commissioner nominee Heidi Overton emerged from her Senate confirmation hearing Thursday (see earlier story) without resolving questions about whether she has enough Republican support to advance — and with a rapidly narrowing window for confirmation before the midterm elections. The Senate Health, Education, Labor and Pensions Committee hearing provided few

FDA Classifies Boston Scientific Imager II Catheter Recall as Class I

FDA has classified Boston Scientific's recall of its Imager II Angiographic Catheters as Class I because a manufacturing problem could cause catheter tips to degrade and detach, potentially resulting in life-threatening complications. The agency announced the Class I classification 9/25, updating an Early Alert it issued

FDA Approves Gazyva for Childhood-Onset Idiopathic Nephrotic Syndrome

FDA has approved Roche’s Gazyva (obinutuzumab) for reducing the risk of relapse in adults and children aged 2 and older with frequently relapsing or steroid-dependent, childhood-onset idiopathic nephrotic syndrome who are in remission. The expanded approval covers the use of the CD20-directed antibody beyond its existing

Read more

Gupta Raises Concerns About Overton’s Independence, Ideology

Overton Confirmation Remains Uncertain After Senate Hearing

FDA Classifies Boston Scientific Imager II Catheter Recall as Class I

FDA Approves Gazyva for Childhood-Onset Idiopathic Nephrotic Syndrome